Arıkan Yorgun Mücella, Mutlu Melek, Toklu Yasin, Cakmak Hasan Basri, Cağıl Nurullah
Ophthalmology Department, Ankara Atatürk Training and Research Hospital, Ankara, Turkey.
Department of Ophthalmology, Yıldırım Beyazıt University, Ankara, Turkey.
Korean J Ophthalmol. 2014 Jun;28(3):275-7. doi: 10.3341/kjo.2014.28.3.275. Epub 2014 May 19.
A 58-year-old man admitted to our opthalmology department with the complaint of branch retinal vein occlusion. He was treated with intravitreal Ozurdex in the right eye. Two days after the injection, the patient presented with ocular pain and the visual acuity was hand movement. A diagnosis of endophthalmitis was made. We performed emergent pars plana vitrectomy (PPV) and the implant was removed from the vitreous cavity using a retinal forceps. A combination of vancomycin 1.0 mg and amikacin 0.4 mg was injected intravitreally. However, because of the blurring in the vitreus one week after the procedure, phacoemulsification and a repeat PPV was performed. Five days after the last procedure the signs and symptoms of endophthalmitis were resolved. Our case demonstrated that endophthalmitis could develop after intravitreal implantation of Ozurdex. Surgical removal of the implant and immediate vitrectomy seems to be a useful treatment option in these cases.
一名58岁男性因视网膜分支静脉阻塞症状入住我院眼科。他接受了右眼玻璃体内注射Ozurdex治疗。注射后两天，患者出现眼痛，视力仅为手动。诊断为眼内炎。我们进行了急诊玻璃体切割术（PPV），并使用视网膜镊从玻璃体腔取出植入物。玻璃体内注射了1.0毫克万古霉素和0.4毫克阿米卡星的联合药物。然而，由于术后一周玻璃体混浊，进行了超声乳化和再次PPV。最后一次手术后五天，眼内炎的体征和症状得到缓解。我们的病例表明，玻璃体内植入Ozurdex后可能发生眼内炎。手术取出植入物并立即进行玻璃体切割术似乎是这些病例中一种有效的治疗选择。
